• Ascletis Pharma initiated a US Phase I trial of oral amylin receptor agonist ASC36 for obesity.
• No clinical results have been presented; the study will generate initial safety, dosing, drug-exposure, and early activity readouts.
• The trial enrolls 86 adults with obesity or overweight, testing single-ascending doses, then multiple-ascending doses.
• Preclinical studies showed meaningful weight loss, supporting the oral program’s differentiation versus injectable amylin competitors.
• Management framed ASC36 as a strategic validation of its oral peptide delivery platform, extending its metabolic disease pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260908-12324720), on September 08, 2026, and is solely responsible for the information contained therein.